Steven D Nathan1, A Whitney Brown2, Nesrin Mogulkoc3, Flavia Soares4, Ashley C Collins2, Joyce Cheng2, Jake Peterson2, Brenna Cannon2, Christopher S King2, Scott D Barnett2. 1. Advanced Lung Disease Program, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA. Electronic address: steven.nathan@inova.org. 2. Advanced Lung Disease Program, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA. 3. Department of Pulmonology, Ege University Hospital, Bornova, Izmir, Turkey. 4. Advanced Lung Disease Program, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA; Department of Internal Medicine, Federal University of Espirito Santo (UFES), Vitoria, ES, Brazil.
Abstract
BACKGROUND: The course of idiopathic pulmonary fibrosis (IPF) is uncertain with variable patterns of disease progression. We sought to evaluate the prognostic utility of the WBC, a routinely performed lab test, in a well-defined cohort of outpatient IPF subjects. METHODS: We reviewed IPF patient records from two independent ILD centers (Inova Fairfax in Falls Church, VA, USA and Ege University Hospital in Izmir, Turkey) between 2007 and 2018. Demographics, CBC data, and patient outcomes were obtained. Survival differences were analyzed. RESULTS: There were 436 IPF outpatients in the cohort with a median WBC of 8.9 × 109 cells per liter. For pragmatic purposes, patients were categorized into two groups, WBC ≥9 or WBC <9. Patients with WBC <9 had a median transplant-free survival of 50.5 months from the time of the CBC, compared to 32.4 months for those with WBC ≥9 (p < 0.0001). The association between WBC and attenuated survival remained significant after adjusting for GAP stage, steroid use, and antifibrotic use when WBC was analyzed both as a continuous (HR: 1.11; 95% CI: 1.05-1.17) and a dichotomized variable (high (WBC ≥9) vs. low (WBC <9), (HR: 1.53; 95% CI:1.09-2.15). WBC and absolute neutrophil count (ANC) were highly correlated suggesting that PMNs account for most of this association (r = 0.92). CONCLUSIONS: Baseline WBC may impart important and readily available prognostic information in outpatients with IPF. Further studies are warranted to validate this as a potential biomarker for IPF, as well as to define the biologic basis for the association.
BACKGROUND: The course of idiopathic pulmonary fibrosis (IPF) is uncertain with variable patterns of disease progression. We sought to evaluate the prognostic utility of the WBC, a routinely performed lab test, in a well-defined cohort of outpatient IPF subjects. METHODS: We reviewed IPF patient records from two independent ILD centers (Inova Fairfax in Falls Church, VA, USA and Ege University Hospital in Izmir, Turkey) between 2007 and 2018. Demographics, CBC data, and patient outcomes were obtained. Survival differences were analyzed. RESULTS: There were 436 IPF outpatients in the cohort with a median WBC of 8.9 × 109 cells per liter. For pragmatic purposes, patients were categorized into two groups, WBC ≥9 or WBC <9. Patients with WBC <9 had a median transplant-free survival of 50.5 months from the time of the CBC, compared to 32.4 months for those with WBC ≥9 (p < 0.0001). The association between WBC and attenuated survival remained significant after adjusting for GAP stage, steroid use, and antifibrotic use when WBC was analyzed both as a continuous (HR: 1.11; 95% CI: 1.05-1.17) and a dichotomized variable (high (WBC ≥9) vs. low (WBC <9), (HR: 1.53; 95% CI:1.09-2.15). WBC and absolute neutrophil count (ANC) were highly correlated suggesting that PMNs account for most of this association (r = 0.92). CONCLUSIONS: Baseline WBC may impart important and readily available prognostic information in outpatients with IPF. Further studies are warranted to validate this as a potential biomarker for IPF, as well as to define the biologic basis for the association.
Authors: Andrew Achaiah; Amila Rathnapala; Andrea Pereira; Harriet Bothwell; Kritica Dwivedi; Rosie Barker; Valentina Iotchkova; Rachel Benamore; Rachel K Hoyles; Ling-Pei Ho Journal: BMJ Open Respir Res Date: 2022-06
Authors: Shaney L Barratt; Andrew W Creamer; Huzaifa I Adamali; Anna Duckworth; Janet Fallon; Silan Fidan; Tom Nancarrow; Rebecca Wollerton; Matthew Steward; Bibek Gooptu; Michael Gibbons; Felix Alexander Woodhead; Chris Scotton Journal: BMJ Open Respir Res Date: 2021-11
Authors: Miriana d'Alessandro; Edoardo Conticini; Laura Bergantini; Paolo Cameli; Luca Cantarini; Bruno Frediani; Elena Bargagli Journal: Life (Basel) Date: 2022-02-20
Authors: Qiang Zheng; Ingrid A Cox; Julie A Campbell; Qing Xia; Petr Otahal; Barbara de Graaff; Tamera J Corte; Alan K Y Teoh; E Haydn Walters; Andrew J Palmer Journal: ERJ Open Res Date: 2022-03-14
Authors: Helen I Warheit-Niemi; Summer J Edwards; Shuvasree SenGupta; Carole A Parent; Xiaofeng Zhou; David N O'Dwyer; Bethany B Moore Journal: JCI Insight Date: 2022-02-22